Literature DB >> 29058263

Ki67 targeted strategies for cancer therapy.

C Yang1, J Zhang1, M Ding1,2, K Xu1,2, L Li1, L Mao3,4, J Zheng5.   

Abstract

Ki67 is a well-known proliferation marker for the evaluation of cell proliferation. Numerous studies have indicated that Ki67 index independently predicts cancer progression. Moreover, because Ki67 is highly expressed in malignant cells but almost could not be detected in normal cells, it has become a promising target for cancer therapy. In this review, we summarize recent advances in Ki67 targeted cancer therapy. In particular, we highlight recent development on the exploitation of Ki67 promoter to drive the expression of siRNAs or therapeutic genes in cancer cells specifically. The use of Ki67 as an attractive target opens a new avenue for cancer therapy.

Entities:  

Keywords:  Gene therapy; Ki67; Proliferation; Renal cancer; Target therapy; siRNA

Mesh:

Substances:

Year:  2017        PMID: 29058263     DOI: 10.1007/s12094-017-1774-3

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.340


  94 in total

1.  Analysis of human Ki-67 gene promoter and identification of the Sp1 binding sites for Ki-67 transcription.

Authors:  Dong-Sheng Pei; Guo-Wei Qian; Hui Tian; Jie Mou; Wang Li; Jun-Nian Zheng
Journal:  Tumour Biol       Date:  2011-11-29

2.  Antisense and antigene properties of peptide nucleic acids.

Authors:  J C Hanvey; N J Peffer; J E Bisi; S A Thomson; R Cadilla; J A Josey; D J Ricca; C F Hassman; M A Bonham; K G Au
Journal:  Science       Date:  1992-11-27       Impact factor: 47.728

3.  Challenges and opportunities for local and systemic delivery of siRNA and antisense oligonucleotides.

Authors:  L Sepp-Lorenzino; Mk Ruddy
Journal:  Clin Pharmacol Ther       Date:  2008-09-17       Impact factor: 6.875

4.  Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma.

Authors:  N Rioux-Leclercq; B Turlin; J Bansard; J Patard; A Manunta; J P Moulinoux; F Guillé; M P Ramée; B Lobel
Journal:  Urology       Date:  2000-04       Impact factor: 2.649

5.  Ki67 and BUBR1 may discriminate clinically insignificant prostate cancer in the PSA range <4 ng/ml.

Authors:  Kazuhiro Nagao; Yoshiaki Yamamoto; Tomohiko Hara; Hirotaka Komatsu; Ryo Inoue; Kenji Matsuda; Hiroaki Matsumoto; Takahiko Hara; Shigeru Sakano; Yoshikazu Baba; Hideyasu Matsuyama
Journal:  Jpn J Clin Oncol       Date:  2011-01-12       Impact factor: 3.019

Review 6.  RNA interference in the clinic: challenges and future directions.

Authors:  Chad V Pecot; George A Calin; Robert L Coleman; Gabriel Lopez-Berestein; Anil K Sood
Journal:  Nat Rev Cancer       Date:  2010-12-16       Impact factor: 60.716

7.  Effects of the Ad5 upstream E1 region and gene products on heterologous promoters.

Authors:  Dennis Hoffmann; Christian Jogler; Oliver Wildner
Journal:  J Gene Med       Date:  2005-10       Impact factor: 4.565

8.  Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus.

Authors:  Anna Kanerva; Petri Nokisalmi; Iulia Diaconu; Anniina Koski; Vincenzo Cerullo; Ilkka Liikanen; Siri Tähtinen; Minna Oksanen; Raita Heiskanen; Saila Pesonen; Timo Joensuu; Tuomo Alanko; Kaarina Partanen; Leena Laasonen; Kalevi Kairemo; Sari Pesonen; Lotta Kangasniemi; Akseli Hemminki
Journal:  Clin Cancer Res       Date:  2013-03-14       Impact factor: 12.531

Review 9.  American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.

Authors:  Rowan T Chlebowski; Nananda Col; Eric P Winer; Deborah E Collyar; Steven R Cummings; Victor G Vogel; Harold J Burstein; Andrea Eisen; Isaac Lipkus; David G Pfister
Journal:  J Clin Oncol       Date:  2002-08-01       Impact factor: 44.544

10.  Molecular characterization of the gene locus of the human cell proliferation-associated nuclear protein defined by monoclonal antibody Ki-67.

Authors:  M Duchrow; C Schlüter; C Wohlenberg; H D Flad; J Gerdes
Journal:  Cell Prolif       Date:  1996-01       Impact factor: 6.831

View more
  48 in total

1.  Predicting biological behaviour of newly diagnosed renal masses: a possible role of cell proliferation biomarkers?

Authors:  Riccardo Mastroianni; Aldo Brassetti; Manuela Costantini; Giuseppe Simone
Journal:  Ann Transl Med       Date:  2019-07

2.  KLK11 suppresses cellular proliferation via inhibition of Wnt/β-catenin signaling pathway in esophageal squamous cell carcinoma.

Authors:  Xin He; Fan Meng; Lingyu Qin; Zhile Liu; Xiongjie Zhu; Zhongjian Yu; Yanfang Zheng
Journal:  Am J Cancer Res       Date:  2019-10-01       Impact factor: 6.166

3.  Lnc-ABCA12-8 confers acquired resistance to gefitinib in non-small cell lung cancer by regulating the alternative splicing of fibronectin 1 in the IIICS region.

Authors:  Shuai He; Jingjing Shi; HongHao Zhou; Qingling Li; Lanxiang Wu
Journal:  Cancer Gene Ther       Date:  2022-06-14       Impact factor: 5.987

4.  Establishment of childhood hepatoblastoma xenografts and evaluation of the anti-tumour effects of anlotinib, oxaliplatin and sorafenib.

Authors:  Dou Yang; Feng Chen; Dan Gong; Lei Zeng; Deng Xiang; Yuanqiao He; Leifeng Chen; Jinlong Yan; Shouhua Zhang
Journal:  Pediatr Surg Int       Date:  2022-01-15       Impact factor: 1.827

5.  Nesfatin-1 is a potential diagnostic biomarker for gastric cancer.

Authors:  Xiao-Qing Wang; Yan Zheng; Pei-Fei Fang; Xian-Bing Song
Journal:  Oncol Lett       Date:  2019-12-10       Impact factor: 2.967

6.  NEDD4 triggers FOXA1 ubiquitination and promotes colon cancer progression under microRNA-340-5p suppression and ATF1 upregulation.

Authors:  Meng Yue; Zhennan Yun; Shiquan Li; Guoqiang Yan; Zhenhua Kang
Journal:  RNA Biol       Date:  2021-02-11       Impact factor: 4.652

7.  HOXC-AS2 mediates the proliferation, apoptosis, and migration of non-small cell lung cancer by combining with HOXC13 gene.

Authors:  Bin Liu; Jing Li; Ji-Man Li; Guang-Yuan Liu; Yong-Sheng Wang
Journal:  Cell Cycle       Date:  2021-01-11       Impact factor: 4.534

8.  Promoting roles of long non-coding RNA FAM83H-AS1 in bladder cancer growth, metastasis, and angiogenesis through the c-Myc-mediated ULK3 upregulation.

Authors:  Beibei Liu; Wuyue Gao; Wei Sun; Liqiang Li; Chao Wang; Xiaohuai Yang; Jianmin Liu; Yuanyuan Guo
Journal:  Cell Cycle       Date:  2020-12-08       Impact factor: 4.534

9.  Increased Tumor Growth Rate and Mesenchymal Properties of NSCLC-Patient-Derived Xenograft Models during Serial Transplantation.

Authors:  José Miguel Pardo-Sánchez; Nuria Mancheño; José Cerón; Carlos Jordá; Emilio Ansotegui; Óscar Juan; Sarai Palanca; Antonio Cremades; Carolina Gandía; Rosa Farràs
Journal:  Cancers (Basel)       Date:  2021-06-14       Impact factor: 6.639

10.  Radiomic analysis of Gd-EOB-DTPA-enhanced MRI predicts Ki-67 expression in hepatocellular carcinoma.

Authors:  Yanfen Fan; Yixing Yu; Ximing Wang; Mengjie Hu; Chunhong Hu
Journal:  BMC Med Imaging       Date:  2021-06-15       Impact factor: 1.930

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.